$2.31 Billion is the total value of Vivo Capital, LLC's 59 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 15.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TIL | Instil Bio Inc | $241,245,000 | -23.0% | 12,486,787 | 0.0% | 10.44% | -5.1% | |
| ALXO | ALX Oncology Holdings Inc | $230,752,000 | -25.8% | 4,220,048 | 0.0% | 9.99% | -8.7% | |
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $200,793,000 | -6.4% | 1,526,359 | -8.3% | 8.69% | +15.3% |
| AMRS | Sell | Amyris, Inc | $190,546,000 | -24.2% | 11,639,929 | -11.6% | 8.25% | -6.6% |
| NFH | New Frontier Health Corp | $159,731,000 | -1.2% | 14,300,000 | 0.0% | 6.92% | +21.8% | |
| HRMY | Harmony Biosciences Holdings Inc | $128,004,000 | -14.6% | 4,534,341 | 0.0% | 5.54% | +5.2% | |
| GTH | Genetron Holdings Ltdads | $127,685,000 | -6.2% | 6,339,860 | 0.0% | 5.53% | +15.6% | |
| TARS | Sell | Tarsus Pharmaceuticals Inc | $86,573,000 | -17.2% | 2,987,331 | -7.9% | 3.75% | +2.0% |
| ALGS | Aligos Therapeutics Inc | $72,306,000 | -10.4% | 3,547,030 | 0.0% | 3.13% | +10.4% | |
| BOLT | Bolt Therapeutics Inc | $59,850,000 | -53.0% | 3,871,291 | 0.0% | 2.59% | -42.1% | |
| KALV | KalVista Pharmaceuticals Inc. | $44,645,000 | -6.7% | 1,863,296 | 0.0% | 1.93% | +14.9% | |
| EPIX | Sell | Essa Pharma Inc | $44,331,000 | -26.2% | 1,551,680 | -25.0% | 1.92% | -9.1% |
| LEGN | Sell | Legend Biotech Corp Sponsoredsponsored ads | $39,273,000 | -50.9% | 956,702 | -65.3% | 1.70% | -39.5% |
| SVA | Sinovac Biotech Ltd. | $38,173,000 | 0.0% | 5,900,000 | 0.0% | 1.65% | +23.1% | |
| ISEE | Iveric Bio Inc | $37,649,000 | +2.1% | 5,966,527 | 0.0% | 1.63% | +25.8% | |
| SRRA | Sierra Oncology, Inc | $37,325,000 | +13.0% | 1,917,074 | 0.0% | 1.62% | +39.2% | |
| OLMA | Olema Pharmaceuticals Inc | $34,655,000 | -15.7% | 1,238,575 | 0.0% | 1.50% | +3.9% | |
| CRNX | Sell | Crinetics Pharmaceuticals Inc | $33,032,000 | -2.4% | 1,752,346 | -20.9% | 1.43% | +20.3% |
| TERN | Terns Pharmaceuticals Inc | $32,797,000 | -44.3% | 2,675,133 | 0.0% | 1.42% | -31.3% | |
| CLDX | Sell | Celldex Therapeutics Inc | $32,400,000 | +21.7% | 968,906 | -25.0% | 1.40% | +50.1% |
| ZLAB | Zai Lab Ltd ADRadr | $30,973,000 | +32.6% | 175,000 | 0.0% | 1.34% | +63.3% | |
| IMPL | New | Impel NeuroPharma Inc | $25,530,000 | – | 2,884,789 | +100.0% | 1.10% | – |
| ACRS | Sell | Aclaris Therapeutics, Inc. | $24,132,000 | -41.9% | 1,374,279 | -16.6% | 1.04% | -28.4% |
| KDMN | Kadmon Holdings Inc | $22,514,000 | -0.5% | 5,817,459 | 0.0% | 0.98% | +22.6% | |
| VRNA | Verona Pharma PLC ADRads | $19,937,000 | -21.8% | 3,048,507 | 0.0% | 0.86% | -3.7% | |
| AVDL | Avadel Pharmaceuticals PLCadr | $19,767,000 | -25.6% | 2,937,093 | 0.0% | 0.86% | -8.3% | |
| NVAX | Sell | Novavax Inc | $18,693,000 | -34.5% | 88,046 | -44.1% | 0.81% | -19.4% |
| GRCL | Sell | Gracell Biotechnologies Incsponsored ads | $17,267,000 | -26.4% | 1,328,257 | -12.8% | 0.75% | -9.3% |
| NKTX | Nkarta Inc | $16,232,000 | -3.7% | 512,225 | 0.0% | 0.70% | +18.8% | |
| EIGR | Eiger BioPharmaceuticals Inc | $15,262,000 | -3.7% | 1,791,257 | 0.0% | 0.66% | +18.7% | |
| CYTK | Cytokinetics Inc | $13,853,000 | -14.9% | 700,000 | 0.0% | 0.60% | +4.9% | |
| MREO | Mereo Biopharma Group PLCads | $13,380,000 | -5.9% | 4,220,938 | 0.0% | 0.58% | +15.8% | |
| CRIS | Curis Inc | $12,537,000 | -28.7% | 1,553,500 | 0.0% | 0.54% | -12.1% | |
| KDNY | Sell | Chinook Therapeutics Inc | $12,315,000 | -34.3% | 872,151 | -27.7% | 0.53% | -19.1% |
| DYN | Dyne Therapeutics Inc | $12,154,000 | +35.5% | 577,642 | 0.0% | 0.53% | +67.0% | |
| ARQT | Sell | Arcutis Biotherapeutics Inc | $11,833,000 | -45.1% | 433,585 | -41.8% | 0.51% | -32.4% |
| ARWR | Arrowhead Pharmaceuticals Inc | $11,380,000 | +24.9% | 137,411 | 0.0% | 0.49% | +54.1% | |
| KURA | Kura Oncology Inc | $10,952,000 | -26.2% | 525,262 | 0.0% | 0.47% | -9.2% | |
| DSGN | Design Therapeutics | $10,561,000 | -33.5% | 530,991 | 0.0% | 0.46% | -18.1% | |
| VALN | New | Valneva SEsponsored ads | $10,540,000 | – | 400,000 | +100.0% | 0.46% | – |
| ZYME | Zymeworks Inc | $9,924,000 | +9.9% | 286,064 | 0.0% | 0.43% | +35.2% | |
| ASLN | Aslan Pharmaceuticals Ltdads | $9,375,000 | -1.5% | 2,840,909 | 0.0% | 0.41% | +21.6% | |
| MRUS | Buy | Merus NV | $9,313,000 | +154.7% | 442,000 | +152.6% | 0.40% | +214.8% |
| CDXS | Codexis, Inc | $8,795,000 | -1.0% | 388,144 | 0.0% | 0.38% | +22.1% | |
| STSA | Satsuma Pharmaceuticals Inc | $8,688,000 | +19.3% | 1,232,394 | 0.0% | 0.38% | +46.9% | |
| PASG | Sell | Passage Bio Inc | $8,553,000 | -65.4% | 646,001 | -54.3% | 0.37% | -57.4% |
| LRMR | Larimar Therapeutics Inc | $7,853,000 | -32.8% | 799,662 | 0.0% | 0.34% | -17.3% | |
| ELEV | New | Elevation Oncology Inc | $6,742,000 | – | 496,843 | +100.0% | 0.29% | – |
| AUPH | Aurinia Pharmaceuticals Inc. | $6,489,000 | -0.2% | 500,732 | 0.0% | 0.28% | +22.7% | |
| FIXX | Homology Medicines, Inc. | $6,202,000 | -22.7% | 853,143 | 0.0% | 0.27% | -5.0% | |
| ORTX | Orchard Therapeutics plcads | $5,820,000 | -39.5% | 1,325,736 | 0.0% | 0.25% | -25.4% | |
| IMVT | Immunovant Inc | $5,632,000 | -34.1% | 532,847 | 0.0% | 0.24% | -18.7% | |
| SNDX | Syndax Pharmaceuticals Inc | $5,494,000 | -23.2% | 320,000 | 0.0% | 0.24% | -5.2% | |
| TXG | 10X Genomics Inc | $2,898,000 | +8.2% | 14,798 | 0.0% | 0.12% | +33.0% | |
| CALT | Sell | Calliditas Therapeutics ADRsponsored ads | $1,835,000 | -78.6% | 62,306 | -80.0% | 0.08% | -73.8% |
| ZGNX | Zogenix Inc | $1,814,000 | -11.5% | 105,000 | 0.0% | 0.08% | +9.7% | |
| DTIL | Precision Biosciences Inc | $1,756,000 | +20.9% | 140,255 | 0.0% | 0.08% | +49.0% | |
| TCDA | Tricida, Inc. | $755,000 | -18.3% | 174,763 | 0.0% | 0.03% | +3.1% | |
| MTCR | Metacrine Inc | $556,000 | -38.8% | 146,426 | 0.0% | 0.02% | -25.0% | |
| IGMS | Exit | IGM Biosciences Inc | $0 | – | -20,000 | -100.0% | -0.05% | – |
| VYNE | Exit | VYNE Therapeutics Inc | $0 | – | -234,877 | -100.0% | -0.06% | – |
| CNST | Exit | Constellation Pharmaceutical | $0 | – | -140,298 | -100.0% | -0.12% | – |
| ATRC | Exit | Atricure Inc | $0 | – | -64,573 | -100.0% | -0.15% | – |
| KALA | Exit | Kala Pharmaceuticals, Inc. | $0 | – | -786,883 | -100.0% | -0.19% | – |
| CGEM | Exit | Cullinan Management Inc | $0 | – | -250,000 | -100.0% | -0.37% | – |
| AKRO | Exit | Akero Therapeutics Inc | $0 | – | -673,280 | -100.0% | -0.69% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.